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Tumor necrosis factor–related apoptosis inducing ligand (TRAIL) is considered to be
a promising antitumor drug because of its selective proapoptotic properties on tumor
cells. However, the clinical application of TRAIL is until now limited because of the
resistance of several cancer cells, which can occur at various levels in the TRAIL
signaling pathway. The role of decoy receptors that can side-track TRAIL, thereby
preventing the formation of an activated death receptor, has been extensively studied. In
this study, we have focused on extracellular vesicles (EVs) that are known to play a role
in cell-to-cell communication and that can be released by donor cells into the medium
transferring their components to recipient cells. TRAIL-induced apoptotic signaling is
triggered upon the binding of two death receptors, DR4 and DR5. Here, we found
that DR5 but not DR4 is present in the conditioned medium (CM)–derived from various
cancer cells. Moreover, we observed that DR5 was exposed on EVs and can act as
“decoy receptor” for binding to TRAIL. This results in a strongly reduced number of
apoptotic cells upon treatment with DR5-specific TRAIL variant DHER in CM. This
reduction happened with EVs containing either the long or short isoform of DR5. Taken
together, we demonstrated that colon rectal tumor cells can secrete DR5-coated EVs,
and this can cause TRAIL resistance. This is to our knowledge a novel finding and
provides new insights into understanding TRAIL sensitivity.
Keywords: extracellular vesicles, DR5, TRAIL, apoptosis, conditioned medium, receptor–ligand trafficking
INTRODUCTION
The secretion of extracellular vesicles (EVs) is an evolutionally conserved process spanning
from bacteria to humans and plants (Rivera et al., 2010; Van Niel et al., 2018; Cui et al.,
2019). The significance of EVs on the one hand relates to their capacity to eliminate unwanted
components from the cell and on the other hand to their capability to communicate with
other cells by exchanging components–from DNA to protein–and thereby influencing the signal
transduction pathways of target cells (Colombo et al., 2014; Yáñez-Mó et al., 2015). They are
highly heterogeneous and can be broadly divided into two main categories based on their
biogenesis and characterizations (Colombo et al., 2014; Van Niel et al., 2018). The term exosomes
(30–100 nm) was first used to describe the EVs released by reticulocytes during differentiation
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 May 2020 | Volume 8 | Article 318
fcell-08-00318 May 15, 2020 Time: 17:18 # 2
Setroikromo et al. DR5-Coated Vesicles as Decoy Receptors
(Johnstone et al., 1987). It originates from inward budding of
endosome membrane creating the so-called cargo-containing
intraluminal vesicle (ILV) inside the early endosome. These
early endosomes can either be directed to the lysosomes or
fused together and mature to the late multivesicular endosomes
(MVEs). MVEs when fused with cell membrane can release
their cargo-containing ILV in the extracellular space, and these
small vesicles are called exosomes (McGough and Vincent,
2016). The other group of EVs is named microvesicles (50–
1,000 nm, up to 10 µm), which are directly formed after budding
or fission of plasma membrane in response to diverse cell
stimulation; this includes the apoptotic bodies. Owing to their
varied compositions, increasing evidence shows that EVs act as
signaling vesicles not only in normal cell homeostasis but also in
many pathological conditions (Cocucci et al., 2009).
Cancer is a diverse group of diseases caused by proliferating
cells traditionally treated with chemotherapy and/or
radiotherapy. These, however, also give harmful side effects to
healthy cells. More preferred therapeutics are being developed in
such a way that they selectively target cancer cells and treatment
with tumor necrosis factor–related apoptosis inducing ligand
(TRAIL) is considered to be promising because of its naturally
proapoptotic properties specifically directed to cancer cells
(Wong et al., 2019). Binding of TRAIL to two death receptors
(DR4 and DR5) triggers the recruitment of Fas-associated
death domain and subsequent pro–caspase-8. This complex,
also known as death-inducing signaling complex (DISC), will
initiate downstream caspase-dependent apoptotic signaling and
eventually leads to cell death (Nagata, 1997). Although cancer
cells are more prone to TRAIL-induced cell death than normal
cells, this signaling pathway can be interrupted by many other
factors that lead to resistance in several cancer cells. For instance,
three decoy receptors (DcR1, DcR2, and OPG) can also bind
to TRAIL and thereby decrease the availability of free TRAIL
for the binding to the death receptors, leading to inhibition of
apoptosis (Mahalingam et al., 2009). Despite the importance
of this classical ligand–receptor binding to induce apoptosis,
ligand-induced receptor internalization, and/or intercellular
receptor trafficking are also important for adequate transduction
of the apoptosis signaling. Likewise, nuclear localization of
DR5 by importin β1 decreases TRAIL-induced cell death in
human tumor cells (Kojima et al., 2011). The presence of death
receptors in autophagosomes rather than plasma prevents
TRAIL-induced apoptosis in breast cancer cells (Di et al.,
2013). In addition, the surface levels of DR4 are controlled by
MARCH-8–mediated ubiquitination, which results in differential
endosomal trafficking of surface DR4 and DR5, and thereby
regulates the resistance to TRAIL (Van De Kooij et al., 2013).
Given the evidences that degradation and secretion of death
receptors are important for the extent of the apoptosis signaling,
we want to know if death receptors are secreted and expressed
on the surface of EVs.
In this study, we demonstrate that DR5 molecules
are on the surface of EVs, and these can compete
with the DR5 on target cells for TRAIL binding,
leading to a decrease of the apoptosis signaling. These
findings contribute a new insight into mechanisms of
TRAIL resistance.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Human colorectal carcinoma cell lines (Colo205, HCT 116,
and DLD-1), human Burkitt lymphoma B cell line (BJAB),
and the Chinese hamster ovary cell line (CHO) were cultured
in RPMI1640 medium supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100 µg/mL streptomycin in
a humidified incubator at 37◦C with 5% CO2. All materials
mentioned above were purchased from Thermo Fisher Scientific
(Waltham, MA, United States). BJAB cell lines, the wild-type cells
BJAB (BJAB WT), BJAB overexpressing DR5 (BJAB DR5), and
a deficient DR5 short isoform (BJAB DR5s DEF) were kindly
provided by Dr. Andrew Thornburn (University of Colorado
Health Sciences Centre, Aurora, CO, United States). CHO cell
lines, the wild-type cells (CHO WT), a mutant overexpressing
DR5 long isoform (CHO TV1), and a mutant overexpressing
DR5 short isoform (CHO TV2) were provided by Organon
(Oss, Netherlands).
Reagents
Soluble (aa 114–281) wild-type TRAIL (TRAIL WT), DR4-
specific TRAIL variant (4C7), and DR5-specific TRAIL variant
(DHER) were constructed and produced as previously described
(Van Der Sloot et al., 2006; Reis et al., 2010).
Collecting Conditioned Medium and
Isolation of EVs
Cells were cultured at the concentration of 150,000 cells/mL
in exosome-free medium for 48 h in humidified incubator
at 37◦C with 5% carbon dioxide. Medium was collected and
spun down at 250 g for 10 min to discard the floating cells.
This supernatant is from now on called conditioned medium
(CM). EVs were isolated by differential centrifugation strategy:
first, sedimentation of CM at 3,000 g for 15 min; second,
sedimentation of the supernatant at 17,000 g for 20 min; and
finally with ultracentrifugation at 30,000 g for 3 h. From the last
run, the pellet was used as EVs and resuspended in phosphate-
buffered saline (PBS) and stored at−80◦C.
Cell Viability Assay
Cell viability assays were conducted using MTS assay. Cells
were seeded in triplicate in 96-well plates at the density of
10,000 cells/mL in medium and incubated in a humidified
incubator at 37◦C with 5% CO2. The following day, cells were
treated with TRAIL WT or variants for 24 h, and assayed
for viability with MTS reagent according to the manufacturer’s
instruction (Promega, Madison, WI, United States). The cell
viability was determined by measuring the absorbance at
490 nm using a microplate reader (Thermo Labsystems, Helsinki,
Finland).
Western Blot
Cells were harvested and lysed with RIPA buffer supplemented
with EDTA-free proteinase inhibitor cocktail (Roche, Basel,
Switzerland). Samples were loaded on precast 4 to 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gels (Thermo
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Fisher Scientific) and transferred onto 0.45 µm nitrocellulose
membrane. Next, the membranes were blocked for 1 h at
room temperature in 5% non-fat milk and probed overnight at
4◦C. The following primary antibodies were used: DR5 (Sigma,
Zwijndrecht, Netherlands), DR4 (Imgenix, Cambridge, United
Kingdom), histone H2A (Abcam, Cambridge, United Kingdom),
and CD63 (Pharmingen, San Diego, CA, United States). After
incubating with secondary antibodies, membranes were detected
using Pierce ECL kit (Thermo Fisher Scientific).
Apoptotic Assay
Apoptosis induction was measured using annexin V–fluorescein
isothiocyanate (FITC) staining and quantified by flow cytometry.
Cells were seeded in six-well plates overnight prior to the
treatment. The next day, cells were treated with TRAIL variant for
24 h. After treatment, cells were collected, washed with PBS twice,
and incubated for 20 min with annexin V–FITC solution on ice.
The cells were analyzed using a FACS Calibur flow cytometer (BD
Biosciences, Franklin Lakes, NJ, United States).
Detection of DRs on EVs by
Transmission Electron Microscopy
The isolated EV suspension was incubated with DR5 antibody
(ENZO life sciences, Bruxelles, Belgium) and placed as a drop
gently on formvar/carbon-coated nickel grid for 60 min. The
grids were washed three times with 0.1% exosome-free bovine
serum albumin PBS solution and incubated for 10 min in 2%
paraformaldehyde. The grids were washed three times with PBS
and incubated for 40 min with secondary antibody conjugated
with 10-nm gold particles. The grids were washed 3 times with
PBS and post fixated with 2.5% glutaraldehyde for 10 min and 2%
uranyl acetate for 15 min. The excess liquid was gently removed
from the grids and dried before analyzing under transmission
electron microscope.
FIGURE 1 | Conditioned medium inhibits DR5-mediated apoptosis in Colo205 cells. Colo205 (A, upper) and BJAB cells (A, below) were treated with TRAIL DHER
variant for 24 h in the presence of fresh medium (FM) or conditioned medium derived from either Colo205 (CMc), BJAB expressing both DR5 isotypes (CMb DR5), or
BJAB cells deficient for DR5 short isoform (CMb DR5s DEF) cells. Conditioned medium was collected after cultivation of cells at a density of 150,000 cells/mL for
48 h. Cell death was measured by MTS assay. Data expressed as the mean ± SD of triplicate samples. Similar results were obtained in three independent
experiments. (B) Total cell extract and conditioned medium (CM) of three colon carcinoma cell lines (upper) and Burkitt lymphoma cell lines (below) were analyzed for
DR4, DR5, and H2A expression with Western blot. The absence of H2A in CM indicates no contamination of cellular nucleosome proteins. Similar results were
obtained in three independent experiments.
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Data Analysis
Data are presented as mean ± SD from triplicates in one
experiment, and experiments were repeated three times. P values
were analyzed by two-way analysis of variance in Tukey multiple
comparisons with GraphPad Prism version 7.0 (San Diego, CA,
United States). ∗∗p ≤ 0.01, ∗∗∗ p ≤ 0.001, and ∗∗∗∗p ≤ 0.0001.




DR5-Mediated Cell Death in Cancer Cells
Most cancer cells release EVs, and the mode of action of those
organelles depends on their cargo proteins (Raposo et al., 1996;
Denzer et al., 2000; Rivoltini et al., 2016). We hypothesize
FIGURE 2 | Long and short isoforms of DR5 in conditioned medium protect
against DR5-mediated apoptosis. (A) Western blot analysis of the expression
of DR5 long and short isoforms of CHO wild-type (WT), CHOTV1, and CHO
TV2 mutants in total cell lysate or in conditioned medium (CM). (B) Colo205
cells were treated with 10 ng/mL DHER (black) or 4C7 (gray) TRAIL variants
for 24 h in the presence of fresh medium or conditioned medium derivate from
either Colo205, CHO TV1, or CHO TV2 cells. Apoptosis was measured by
annexin V staining. Data expressed as the mean ± SD of triplicate samples.
Similar results were obtained in three independent experiments.
that secreted death receptors displayed via the EVs can act as
decoy receptors and therefore reduce the apoptosis signaling.
We cultivated Colo205 and BJAB cells at the concentration of
150,000 cells/mL in exosome-free medium for 48 h, and the
medium was collected and used as CM. Colo205 and BJAB cells
were treated for 24 h with DR5 TRAIL variant (DHER) in fresh
medium or CM derived either from Colo205 (CMc) or BJAB
(CMb). We examined the cell viability of Colo205 and BJAB cells
with MTS assay. We also used in this experiment BJAB mutants
that expressed respectively only the DR5 long isoform (CMb
DR5s DEF) or both isoforms (CMb DR5). We observed in both
TRAIL-treated cells incubated in fresh medium considerable
higher percentages of cell death than in cells grown in CM. This
protection was observed for CM derived from Colo205 as from
BJAB cells. The protective effect of CM was dose dependent
and most prominent at 10 ng/mL DHER for Colo205 and for
BJAB DR5 cells at 50 ng/mL (Figure 1A). This indicates that the
CM contains factors that are able to inhibit DR5-mediated cell
death signaling. Interestingly, Western blot analysis of the CM
from three different colon carcinoma cells (Colo2015, HCT116,
and DLD-1) and BJAB mutants revealed that only DR5 was
secreted in significant levels in CM, and DR4 levels were almost
negligible (Figure 1B). Next, the long DR5 isoform seems to be
sufficient for this protective effect as cells expressing only the
long isoform (BJAB DR5s DEF) were also able to reduce the cell
death. The absence of H2A in the supernatant confirms the purity
of the sample preparation and absence of cellular nucleosome
proteins in the CM.
FIGURE 3 | Colo205 conditioned medium contains DR5-coated extracellular
vesicles. Negative staining of EVs isolated from conditioned medium (upper
picture). Bottom pictures are the zoom pictures of single EV stained with
gold-labeled DR5 antibody (white arrows) and detected by transmission
electron microscope. Scale bar is 500 nm. The experiment was repeated
three times, and several EVs were analyzed.
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Both Long and Short Isoforms of DR5 in
CM Contribute to TRAIL Resistance
We have concluded that CM can prevent DR5-mediated cell
death. To explore which isoforms of DR5 contribute to this
resistance phenomenon, we used CHO cells expressing either
the human long, or the short DR5 isoforms. Immunostaining
with DR5 antibodies confirmed the expression of the different
DR5 isotypes in total cell lysates of CHO mutants (CHO-TV1
and CHO-TV2), and both isotypes were secreted into the CM
(Figure 2A). Treatment of Colo205 cells with 10 ng/mL TRAIL
DHER variant in CM derived from Colo205, CHO-TV1, or
CHO-TV2 cells resulted in significant inhibition of apoptosis
compared to fresh medium or CM derived from CHO wild-
type cells (CHO-WT CM), which lack both DR5 isoforms. This
protective effect was specifically related to DR5, as no protection
was observed with the 4C7 variant, which can induce apoptosis
only via DR4 receptor (Figure 2B). The protective effect of
CHO-TV1–derived CM versus CHO-WT–derived CM was at the
same magnitude as COLO205-derived CM versus fresh medium.
The short isoform (CHO-TV2) showed a slightly lower protective
effect. We were not able to quantify the precise concentration of
DR5 in the CMs, and therefore we only can conclude that both
long and short isoforms of DR5 contribute to TRAIL-resistance
mechanism of Colo205 cells.
DR5 Is Expressed at the Surface of EVs
To investigate whether DR5 was secreted out of the cells as
soluble receptors or packed into vesicles, we fractionated the
CM by differential centrifugation strategy and analyzed it with
transmission electron microscope. The smallest vesicles ranging
from 30 to 300 nm were sedimented by ultracentrifugation
at 100,000 g. Bigger particles were first removed stepwise
at lower speeds to avoid artificial small vesicles formation
(Livshits et al., 2016). After negative staining various exosome-
like vesicles, characteristics such as donut-like structures with
different sizes, and shapes were observed (Figure 3, upper
picture). Next, we asked whether secreted EVs are coated with
DR5. Immunostaining with gold-labeled DR5 antibody showed
FIGURE 4 | DR5-coated EVs inhibit TRAIL-induced apoptosis. (A) Colo205 cells treated with TRAIL DHER in fresh medium (FM), conditioned medium (CM), or
conditioned medium after ultracentrifuging (UC) and apoptotic cells were determined by annexin V staining. (B) Colo205 cells were cultured in CM containing either
EVs (CM + EV) or depleted of EVs (CM - EV) and followed by the treatment with TRAIL DHER or TRAIL wild type (WT). Cell death was measured by MTS assay.
(C) Western blot of CD63. Data expressed as the mean ± SD of triplicate samples. Similar results were obtained in three independent experiments.
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DR5 at the surface of the EVs, visible as dark spots at the surface
of the EV (Figure 3, bottom pictures).
Depletion of EVs in CM Restores the
TRAIL DHER Sensitivity of Colo205 Cells
To confirm that the secreted EVs coated DR5 are responsible
for the protection against cell death, we depleted EVs from CM
and treated the cells with TRAIL DHER. Removing EVs from
CM by sedimentation nullified completely the protective effect
of CM upon TRAIL DHER treatment in Colo205 (Figure 4A).
This protective effect was again observed when purified EVs were
supplemented to fresh medium in Colo205 cells treated with
TRAIL DHER or TRAIL wild type (Figure 4B). CD63 was used
as positive control for the isolation of EVs (Figure 4C).
DISCUSSION
In the present study, we showed EVs coated with DR5 receptors
can reduce the TRAIL-mediated apoptosis in cancer cells. This
inhibition of the EVs was specific when apoptosis is triggered
by DR5. TRAIL 4C7 variant, which triggers apoptosis via DR4,
was not inhibited by CM. Both long and short isoforms of
DR5 contribute to the inhibition of TRAIL-mediated apoptosis.
This is the first report demonstrating the expression of DR5 on
the surface of EVs, providing a new insight into the TRAIL-
resistance phenomenon.
The endocytosis of TRAIL-DR complex and its importance
on triggering the apoptosis signaling have been studied
extensively. However, there are conflicting reports as to whether
internalization of TRAIL-DR complex results either in inhibiting
or enhancing the apoptotic signals depending on the cell
types (Austin et al., 2006; Kohlhaas et al., 2007; Reis et al.,
2017). One study showed that DR-mediated caspase activation
rapidly disrupts clathrin-mediated endocytosis (CME), which in
turn enhanced the apoptotic signals downstream of the DISC
complexs (Austin et al., 2006). Recently, another study unraveled
the molecular mechanism of CME-dependent endocytosis of
death receptors. They showed that endocytosis of TRAIL-
DR complex requires dynamin-1 protein, which is activated
by ryanodine receptor-mediated Ca2+ release in response
to caspase-8 activation. However, this selective regulation of
TRAIL-DR endocytosis suppresses TRAIL-mediated apoptosis
(Reis et al., 2017).
Internalized receptor complexes in the endocytic pathway
can undergo different routes: receptors can be processed and
recycled back to the surface or enter the degradation machinery.
Ubiquitination of ligand–receptor complexes plays an important
role in the endosomal sorting mechanism into MVE to direct
the cargo toward the degradation machinery and in this way
determine the fate of the protein. A study reported that the
membrane-associated RING-CH ubiquitin ligase 8 (March-8)
regulates the cell surface expression of DR4 and targets DR4
to the lysosomal degradation machinery (Van De Kooij et al.,
2013). Interesting in their study was that March-8 had noticeable
less preference for targeting DR5. Lys-273 at the cytoplasmic tail
of DR4 is an important ubiquitin acceptor sites for March-8,
and DR5 has no Lys-273 residue or homolog at membrane-
proximal locations. Therefore, inefficient targeting of DR5 to
lysosomes may be the reason that DR5 is preferentially displayed
at EVs. Apart from internalization of receptors, receptors can
also be released in the medium by exocytosis. This involves the
release of small vesicle-like structure, which carries biomolecules
such as plasma membrane receptors and other proteins into the
extracellular space. The effect of the secreted DR-coated EVs on
the apoptosis signaling has hardly been studied and may explain
the variation in TRAIL response of cancer cells. Proteomic
database search in Vesiclepedia1 revealed that DR5 is present in
exosomes of several cancer cells from brain, colorectal, kidney,
glioblastoma, ovarian, prostate, lung, leukemia, and melanoma
cancer. However, no functional biological data exist on the
influence of DRs on EVs on TRAIL sensitivity. Despite the
interesting findings of differential endocytosis and ubiquitination
of DRs, more research should be done to understand the
mechanism of intracellular receptors trafficking. Together with
the new insight in TRAIL-resistance mechanism by DR5-coated
EVs, TRAIL treatment in combination with inhibitors preventing
secretion of EVs could be a promising combination strategy to
treat TRAIL-resistant cancer cells.
In summary, we have uncovered the role of DR5-coated EVs in
the resistance of cancer cells for TRAIL treatment. Secreted DR5-
coated EVs inhibit TRAIL sensitivity of colon cancer cells. This
protective effect was specific for DR5, as DR4 was absent in CM.
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